LXRX logo

Lexicon Pharmaceuticals (LXRX)

Profile

Full Name

Lexicon Pharmaceuticals, Inc.

Ticker Symbol

LXRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

April 7, 2000

Indexes

Not included

Website

http://www.lexpharma.com

Employees

103

Key Details

Price

$0.51(+2.00%)

Market cap

$184.36M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$31.08M(+2481.48% YoY)

Annual EPS

-$0.63(+21.25% YoY)

PE ratio

-

Next earnings date

May 2, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$0.51
LXRX price is $0.51

30-Day Relative Volume

0.11
LXRX 30-day relative volume is 0.11

Price Performance

Price Most recent change

+2%
LXRX price was up +2% on Apr 17, 2025

Price YTD change

-31.08%
LXRX price is down -31.08% since January 1st

Price 1-year change

-68.52%
LXRX price is down -68.52% year-on-year

Price 3-year change

-78.11%
LXRX price is down -78.11% over the past 3 years

Price Range

Price All-time high

$344.75
LXRX price is currently -99.85% below its historical high of $344.75

Price 3-year low

$0.28
LXRX price is currently +82.14% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$184.36M
LXRX market capitalization is $184.36 million

Market cap 3-year change

-47.11%
LXRX market capitalization is down -47.11% over the past 3 years

Market cap All-time high

$2.25B
LXRX market capitalization is currently -91.79% below its historical high of $2.25 billion

Market cap sector rank

56.13%
LXRX market capitalization is higher than 56.13% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+46.81%
LXRX shares outstanding is up +46.81% year-on-year

Shares Outstanding 3-Year Change

+141.65%
LXRX shares outstanding is up +141.65% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.13
LXRX beta is 1.13

200-day SMA

$1.17
LXRX price is currently -56.50% below its 200-day simple moving average

50-day SMA

$0.51
LXRX price is currently -0.62% below its 50-day simple moving average

RSI

53.25
LXRX 14-day relative strength index is 53.25

Volume

0.11
LXRX 30-day relative volume is 0.11

ATR

$0.07
LXRX average true range is $0.07

10-day Historical Volatility

131.85%
LXRX 10-day historical volatility is 131.85%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$31.08M
LXRX annual revenue is $31.08 million

Revenue Analysts estimate

$8.60M
LXRX annual revenue is currently +261.42% higher than the consensus analysts' forecast

Revenue 1-year change

+2481.48%
LXRX annual revenue is up +2481.48% year-on-year

Revenue Sector rank

39.57%
LXRX annual revenue is higher than 39.57% of companies in Healthcare sector

EPS

EPS

-$0.63
LXRX annual earnings per share is -$0.63

EPS Analysts estimate

-$0.43
LXRX annual earnings per share is currently +47.37% higher than the consensus analysts' forecast

EPS 1-year change

+21.25%
LXRX annual earnings per share is up +21.25% year-on-year

EPS Sector rank

64.29%
LXRX annual earnings per share is higher than 64.29% of companies in Healthcare sector

Profit

Gross profit

$30.46M
LXRX annual gross profit is $30.46 million

Gross margin

98.02%
LXRX annual gross profit margin is 98.02%

Operating profit

-$197.12M
LXRX annual operating income is -$197.12 million

Operating margin

-634.20%
LXRX annual operating profit margin is -634.20%

Net income

-$200.40M
LXRX annual net profit is -$200.40 million

Net margin

-644.78%
LXRX annual net profit margin is -644.78%

Expenses

Total expenses

$228.20M
LXRX annual total expenses is $228.20 million

Operating expenses

$227.58M
LXRX annual total operating expenses is $227.58 million

Cost of goods sold

$616.00K
LXRX annual cost of goods sold is $616.00 thousand

Selling, general & administrative expenses

$143.10M
LXRX annual SGA is $143.10 million

Depreciation and amortization

$534.00K
LXRX annual depreciation & amortization is $534.00 thousand

Interest expense

$15.58M
LXRX annual interest expense is $15.58 million

Income tax

-
LXRX annual income tax value is unknown

EBIT & EBITDA

EBIT

-$184.82M
LXRX annual earnings before interest & taxes is -$184.82 million

EBITDA

-$184.29M
LXRX annual EBITDA is -$184.29 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$298.42M
LXRX annual total assets is $298.42 million

Non current assets

$52.23M
LXRX annual long term assets is $52.23 million

Current assets

$246.19M
LXRX annual total current assets is $246.19 million

Cash and cash equivalents

$66.66M
LXRX annual cash & cash equivalents is $66.66 million

Accounts receivable

$3.47M
LXRX annual accounts receivable is $3.47 million

Inventory

$231.00K
LXRX annual inventory is $231.00 thousand

Liabilities

Total liabilities

$152.47M
LXRX annual total liabilities is $152.47 million

Long term liabilities

$107.22M
LXRX annual total long term liabilities is $107.22 million

Current liabilities

$45.25M
LXRX annual total current liabilities is $45.25 million

Accounts payable

$14.80M
LXRX annual accounts payable is $14.80 million

Debt

Total debt

$108.40M
LXRX annual total debt is $108.40 million

Total debt 1-year change

+2.2%
LXRX annual total debt is up +2.2% year-on-year

Long term debt

$107.22M
LXRX annual long term debt is $107.22 million

Short term debt

$1.18M
LXRX annual short term debt is $1.18 million

Equity & Capital

Shareholders equity

$145.95M
LXRX annual stockholders equity is $145.95 million

Book value

$145.95M
LXRX annual book value is $145.95 million

Retained earnings

-$1.97B
LXRX annual retained earnings is -$1.97 billion

Working capital

$200.94M
LXRX annual working capital is $200.94 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$178.78M
LXRX annual cash flow from operations is -$178.78 million

Cash from operations 1-year change

-10.43%
LXRX annual cash flow from operations is down -10.43% year-on-year

Cash from investing

-$15.38M
LXRX annual cash flow from investing activities is -$15.38 million

Cash from investing 1-year change

+69.21%
LXRX annual cash flow from investing activities is up +69.21% year-on-year

Cash from financing

$238.35M
LXRX annual cash flow from financing activities is $238.35 million

Cash from financing 1-year change

+26.81%
LXRX annual cash flow from financing activities is up +26.81% year-on-year

CAPEX

CAPEX

$1.03M
LXRX annual capital expenditures is $1.03 million

CAPEX 1-year change

+119.36%
LXRX annual capital expenditures is up +119.36% year-on-year

Free Cash Flow

Free cash flow

-$179.81M
LXRX annual free cash flow is -$179.81 million

Free cash flow 1-year change

-10.74%
LXRX annual free cash flow is down -10.74% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

98.02%
LXRX annual gross profit margin is 98.02%

Operating margin

-634.20%
LXRX annual operating profit margin is -634.20%

Net margin

-644.78%
LXRX annual net profit margin is -644.78%

ROA & ROE

ROA

-75.93%
LXRX annual return on assets is -75.93%

ROE

-167.66%
LXRX annual return on equity is -167.66%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
LXRX price to earnings ratio value is unknown

PE ratio Sector rank

-
LXRX price to earnings ratio is unknown

PB Ratio

PB ratio

1.26
LXRX price to book ratio is 1.26

PB ratio Sector rank

50.04%
LXRX price to book ratio is higher than 50.04% of companies in Healthcare sector

PS Ratio

PS ratio

5.93
LXRX price to sales ratio is 5.93

PS ratio Sector rank

69.7%
LXRX price to sales ratio is higher than 69.7% of companies in Healthcare sector

Enterprise value

Enterprise value

$226.10M
LXRX enterprise value is $226.10 million

Enterprise value Sector rank

60.17%
LXRX enterprise value is higher than 60.17% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-1.23
LXRX EV/EBITDA is -1.23

EV/EBITDA Sector rank

39.69%
LXRX EV/EBITDA is higher than 39.69% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

5.44
LXRX annual current ratio is 5.44

Quick ratio

5.44
LXRX annual quick ratio is 5.44

Leverage

Debt to equity

0.69
LXRX annual debt to equity ratio is 0.69

Interest coverage ratio

-11.86
LXRX annual interest coverage ratio is -11.86

Risk & Stability

Piotroski F-Score

3
LXRX piotroski f-score is 3

Altman Z-Score

-9.64
LXRX altman z-score is -9.64

Analyst ratings

Recent major analysts updates

Mar 28, 25 HC Wainwright & Co.
Buy
Mar 7, 25 Piper Sandler
Overweight
Mar 7, 25 Needham
Hold
Mar 7, 25 HC Wainwright & Co.
Buy
Mar 4, 25 Leerink Partners
Market Perform
Mar 3, 25 Needham
Hold
Mar 3, 25 HC Wainwright & Co.
Buy
Jan 29, 25 Needham
Hold
Jan 29, 25 HC Wainwright & Co.
Buy
Dec 23, 24 Needham
Hold

Institutional Ownership

Similar stocks

CGC logo
Canopy Growth (CGC)
HITI logo
High Tide (HITI)
TuHURA Biosciences (HURA)
INGN logo
Inogen (INGN)
DRTS logo
Alpha Tau Medical (DRTS)
ESPR logo
Esperion Therapeutics (ESPR)
TVGN logo
Tevogen Bio Holdings (TVGN)
AMRN logo
Amarin (AMRN)
LUNG logo
Pulmonx (LUNG)
  • What is the ticker symbol for Lexicon Pharmaceuticals?
  • Does Lexicon Pharmaceuticals pay dividends?
  • What sector is Lexicon Pharmaceuticals in?
  • What industry is Lexicon Pharmaceuticals in?
  • What country is Lexicon Pharmaceuticals based in?
  • When did Lexicon Pharmaceuticals go public?
  • Is Lexicon Pharmaceuticals in the S&P 500?
  • Is Lexicon Pharmaceuticals in the NASDAQ 100?
  • Is Lexicon Pharmaceuticals in the Dow Jones?
  • When was Lexicon Pharmaceuticals's last earnings report?
  • When does Lexicon Pharmaceuticals report earnings?
  • Should I buy Lexicon Pharmaceuticals stock now?

What is the ticker symbol for Lexicon Pharmaceuticals?

The ticker symbol for Lexicon Pharmaceuticals is NASDAQ:LXRX

Does Lexicon Pharmaceuticals pay dividends?

No, Lexicon Pharmaceuticals does not pay dividends

What sector is Lexicon Pharmaceuticals in?

Lexicon Pharmaceuticals is in the Healthcare sector

What industry is Lexicon Pharmaceuticals in?

Lexicon Pharmaceuticals is in the Biotechnology industry

What country is Lexicon Pharmaceuticals based in?

Lexicon Pharmaceuticals is headquartered in United States

When did Lexicon Pharmaceuticals go public?

Lexicon Pharmaceuticals's initial public offering (IPO) was on April 7, 2000

Is Lexicon Pharmaceuticals in the S&P 500?

No, Lexicon Pharmaceuticals is not included in the S&P 500 index

Is Lexicon Pharmaceuticals in the NASDAQ 100?

No, Lexicon Pharmaceuticals is not included in the NASDAQ 100 index

Is Lexicon Pharmaceuticals in the Dow Jones?

No, Lexicon Pharmaceuticals is not included in the Dow Jones index

When was Lexicon Pharmaceuticals's last earnings report?

Lexicon Pharmaceuticals's most recent earnings report was on Mar 6, 2025

When does Lexicon Pharmaceuticals report earnings?

The next expected earnings date for Lexicon Pharmaceuticals is May 2, 2025

Should I buy Lexicon Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page